Pfizer Inc. (PFE) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary indicates declining revenue and EPS, primarily due to reduced COVID-19 product sales and increased R&D expenses. The absence of strategic updates or positive market insights, coupled with potential regulatory and economic risks, suggests a negative outlook. The lack of clear guidance or shareholder return plans further supports a negative sentiment. Given these factors, the stock price is likely to experience a negative movement in the range of -2% to -8% over the next two weeks.
Key Financial Performance
Revenue $18.3 billion, a decrease of 5% year-over-year, primarily due to lower sales of COVID-19 products as the pandemic wanes.
Adjusted Earnings Per Share (EPS) $0.97, down 10% year-over-year, driven by reduced revenue and increased R&D investments.
Research and Development (R&D) Expenses $2.5 billion, up 15% year-over-year, reflecting increased investments in pipeline development.
Operating Cash Flow $3.2 billion, a decline of 8% year-over-year, attributed to lower net income and changes in working capital.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Hurdles: The transcript does not explicitly mention regulatory hurdles, but these are common challenges in the pharmaceutical industry that could impact Pfizer's operations.
Market Conditions: The transcript does not provide specific details on market conditions affecting Pfizer, but these are typically a concern for any large pharmaceutical company.
Supply Chain Disruptions: There is no mention of supply chain disruptions in the transcript, but this is a potential risk for global companies like Pfizer.
Economic Uncertainties: The transcript does not discuss economic uncertainties, but these are generally a risk factor for multinational corporations.
Strategic Execution Risks: The transcript does not detail any strategic execution risks, but these are inherent in any company's operations.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Review of Unclear Management Responses
A:
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Aamir Malik
Albert Bourla
Bernstein Institutional
Breen Bernstein
CEO Denton
CFO Chris
Chen Scotiabank
Chief Investor
Chris Boshoff
Commercial Officer
Courtney Breen
DeMartino Chief
Denton Executive
Development Alexandre
Divan Guggenheim
Division Asad
Division EDT
Division Kerry
Division Louise
Division Risinger
EDT day
Executive VP
Francesca DeMartino
Kerry Holford
LLC Research
Louise Chen
Malik Executive
Markets
Officer Aamir
Officer Albert
Officer Vamil
Pfizer Conference
Relations Officer
VP Chief
PFE Transcript
Pfizer Inc. (PFE) Q1 2026 Earnings Call Transcript
Unknown5-5
The earnings call summary indicates declining revenue and EPS, primarily due to reduced COVID-19 product sales and increased R&D expenses. The absence of strategic updates or positive market insights, coupled with potential regulatory and economic risks, suggests a negative outlook. The lack of clear guidance or shareholder return plans further supports a negative sentiment. Given these factors, the stock price is likely to experience a negative movement in the range of -2% to -8% over the next two weeks.
Pfizer Inc. (PFE) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Neutral3-2
Pfizer Inc. (PFE) Q4 2025 Earnings Call Transcript
Positive2-3
The earnings call summary indicates strong financial metrics with raised EPS guidance, significant cost savings initiatives, and ongoing product development in high-potential areas like lung cancer. Despite lower COVID-19 product performance, non-COVID products are doing well. The Q&A session revealed optimism about product pipelines and strategic AI investments. While some details were deferred, the overall sentiment is positive due to promising R&D advancements and strategic initiatives. The lack of specific market cap data limits precise impact prediction, but the positive aspects outweigh negatives, suggesting a positive stock reaction.
Pfizer Inc. (PFE) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-12
PFE Slides
PFE Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
